[{"from": "human", "value": "Describe this molecule. [C][C][C@@H1][Branch2][Ring2][Branch1][N][Branch1][Ring2][C][Ring1][Branch1][C][=N][C][=C][Branch1][#Branch2][C][=N][N][Ring1][Branch1][C][=C][Ring1][=Branch2][N][C][=Branch1][C][=O][N][C][C][C@@H1][Branch1][Ring2][C][Ring1][Branch1][O][C][=C][Branch1][#Branch2][C][=C][C][=Branch1][Ring2][=C][Ring1][=Branch1][F][F]"}, {"from": "gpt", "value": "The molecule is an orally available, tropomyosin receptor kinase (Trk) inhibitor, with potential antineoplastic activity. Upon administration, larotrectinib binds to Trk, thereby preventing neurotrophin-Trk interaction and Trk activation, which results in both the induction of cellular apoptosis and the inhibition of cell growth in tumors that overexpress Trk. Trk, a receptor tyrosine kinase activated by neurotrophins, is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival."}]